CAR-T cell therapy advancements
Qihan Biotech's universal CAR-T therapy, QT-019B, secured three of the FDA's top expedited designations (RMAT, Breakthrough Therapy, and Fast Track) on July 15, 2026, marking a significant advancement in CAR-T cell therapy. As of July 15, 2026, CAR-T cell therapy is expanding beyond hematological malignancies to solid tumors and autoimmune diseases, with new clinical trials enrolling children and young people. China approved satricabtagene autoleucel (satri-cel), the world's first CAR-T therapy for solid tumors, on June 25, 2026, showing tumor shrinkage in 55% of patients in trials. Researchers have identified novel targets like GPNMB and developed modular systems such as GA1CAR for enhanced safety and adaptability, while Tempest plans to unveil its next-generation in vivo CAR-T pipeline with a first clinical study anticipated in Q4 2026.
Timeline
Want updates on this thread?
Track this storyTimeline of developments
July 2026 — 5 developments
Tempest plans next-gen in vivo CAR-T pipeline, clinical study set for Q4 2026
Tempest plans to unveil its next-generation in vivo CAR-T pipeline, with the first clinical study anticipated in the fourth quarter of 2026. The company is exploring CAR-T cell therapy for solid tumors and autoimmune diseases, including in vivo approaches and glycoengineering for enhanced resilience.
New Clinical Trial Launched for Personalized CAR-T Cell Immunotherapy in Solid Tumors
A new clinical trial is enrolling children and young people with solid tumors to test a personalized CAR-T cell immunotherapy. This initiative is part of broader advancements in CAR-T therapy, including exploring its potential in autoimmune diseases and developing new manufacturing platforms.
Qihan Biotech's Universal CAR-T Therapy Receives Three FDA Expedited Designations
Qihan Biotech's universal CAR-T therapy, QT-019B, has secured three of the FDA's top expedited designations: RMAT, Breakthrough Therapy, and Fast Track. This development is part of broader advancements in CAR-T therapy, including modular systems like GA1CAR from the University of Chicago, which offers a "plug-and-play" approach for enhanced safety and adaptability.
New CAR-T Therapy Targets and Platforms Emerge for Solid Tumors
Researchers have identified GPNMB as a novel target for CAR-T cell therapy in solid tumors, showing promise in preclinical models and early clinical trials with disease stabilization in one patient. A new modular 'universal' CAR-T system, GA1CAR, has been developed to separate antigen recognition from signaling machinery, allowing for precise control and redirection of T-cells to different cancer targets with enhanced safety and flexibility. Studies are also exploring HER2-targeted CAR-T cells for solid tumors and a therapy targeting Claudin18.2 for advanced solid tumors, demonstrating preliminary efficacy and tolerability.
Low-Affinity HER2 CAR-T Cells Show Promise for Safer Tumor Targeting in New Study
A study published in Nature Medicine indicates that low-affinity HER2 CAR-T cells can effectively target tumors with high HER2 expression while minimizing toxicity to normal cells. This approach shows promise for treating HER2-high tumors and is being evaluated in clinical trials for advanced sarcoma.
June 2026 — 5 developments
China approves world's first CAR-T therapy for solid tumors, satri-cel
China has approved satricabtagene autoleucel (satri-cel), the world's first CAR-T therapy for solid tumors, targeting Claudin 18.2 (CLDN18.2) and HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma. Clinical trials showed a significant improvement in progression-free survival, with tumors shrinking in 55% of patients, though 99% experienced grade 3 or higher treatment-emergent adverse effects, including cytokine release syndrome in 95%.
Universal CAR-T cells show promise for T-cell malignancies
A universal CAR-T cell platform targeting CD7 has shown promise in patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoma, achieving high overall response rates. This approach aims to overcome the challenges of patient-specific CAR-T manufacturing by using allogeneic donor cells.
New CAR-T Therapy Targeting p95HER2 Awaiting Phase 1 Trials for Solid Tumors
A new CAR-T strategy targeting p95HER2, a protein found in a subset of HER2+ tumors, has shown promise and is awaiting Phase 1 clinical trials. CAR-T therapies targeting HER2 are also being investigated for advanced sarcoma and pancreatic cancer, with early-phase clinical trials showing signs of disease control and manageable toxicity.
CAR-T Therapy Expanded for Transplants and New Cell Types
CAR-T cell therapy is being repurposed for kidney transplant desensitization, demonstrating its use beyond cancer treatment. Advancements include the development of universal and 'off-the-shelf' CAR-T therapies by companies like Vycellix and Wondercel Therapeutics, aiming to overcome immune rejection and improve scalability. The CAR ecosystem is also expanding to include CAR-macrophages and CAR-Tregs for more precise cell therapies.
CAR-T Therapy Advances: NFIL3 Exhaustion Factor Identified, New CAR-M Product Enters Trials
Researchers have identified NFIL3 as a key factor in CAR T-cell exhaustion, with disabling it via CRISPR showing improved efficacy against tumors. Additionally, a modular immunotherapy called GA1CAR has been developed, and a HER2-directed CAR-M product (CT-0508) has entered phase 1 evaluation for solid tumors.
May 2026 — 1 developments
New CAR-T Strategies Explored for Solid Tumors and Universal Applications
Researchers are developing new CAR-T cell therapy strategies for solid tumors, including combinations with mRNA vaccines or oncolytic viruses, and engineering 'armored' CARs to improve efficacy. Genetic modifications, such as deleting the CDKN1B gene, are also being studied to enhance CAR-T cell proliferation and anti-tumor activity.
April 2026 — 10 developments
CAR-T cell therapies anticipate significant growth and refinement over next decade
The development of CAR-T cell therapies for various cancers and autoimmune diseases is anticipated to grow significantly over the next 5-10 years. Research is focusing on refining CAR constructs for improved specificity and reduced toxicity, developing better management protocols for side effects, exploring allogeneic CAR-T platforms for broader access, and enhancing T-cell trafficking for solid tumors.
CAR T-cells show promise in treating HER2-positive breast cancer and T-cell leukemia
A phase 1 trial of intraventricular HER2-directed CAR T-cells for HER2-positive breast cancer with CNS metastases has shown a manageable safety profile and stable disease rates in heavily pretreated patients. Additionally, a new generation of base-edited CAR T-cells (BE-CAR7) shows promise in treating aggressive T-cell leukemia, contributing to the 'CAR-T 2.0 era' focused on rapid manufacturing and reduced toxicity.
C406 CAR-T therapy shows 75% disease control in HER2-positive breast cancer study
The C406 CAR-T therapy targeting HER2-positive breast cancer demonstrated a 75% disease control rate in a phase I study, with manageable adverse events. Ongoing research continues to focus on developing next-generation CAR-T cells, including GA1CAR, for improved persistence, reduced toxicity, and better tumor microenvironment penetration.
Novel CAR-T therapy shows tumor reduction in preclinical models
A novel CAR-T therapy targeting HER2-expressing tumors, engineered to secrete a bispecific antibody against HER2 and p95HER2, has demonstrated significant tumor reduction in preclinical models. A Phase 1 clinical trial for this therapy is currently in development.
New Research Explores Next-Generation CAR-T Therapies for Solid Tumors
New research explores next-generation CAR-T cell therapies targeting HER2 for solid tumors, with one novel CAR-T achieving safe, complete, and durable responses in preclinical models, leading to complete tumor disappearance in xenograft models. Concurrently, new CAR-T manufacturing methods are being developed to improve efficacy and reduce costs, including a multi-cytokine scaffold for longer-lived immune cells and a controlled immune response CAR-T for safer blood cancer treatment.
Novel HER2 CAR T-cell therapy shows efficacy in preclinical solid tumor models and Phase I sarcoma trial
A novel CAR T-cell therapy targeting the HER2 antigen has shown efficacy and safety in preclinical models of HER2-positive solid tumors, including breast and ovarian cancers, and is being explored for integration with radiation therapy. In a Phase I clinical trial for advanced sarcoma, 50% of treated patients experienced clinical benefit, with one patient achieving a durable, cancer-free response lasting over five years.
UCLA Scientists Engineer 'Armored' CAR-T Cells to Combat Tumors
UCLA scientists have developed 'armored' CAR-T cells engineered to overcome the immunosuppressive tumor microenvironment by blocking VEGF. These modified cells demonstrated a significant reduction in tumor growth and extended survival in preclinical models of glioblastoma and ovarian cancer.
University of Chicago researchers develop GA1CAR, a modular CAR-T system for blood cancers
A universal CAR-T cell immunotherapy has shown promising results in a Phase 1/2 clinical trial for aggressive blood cancers, with most patients achieving full remission. Additionally, an "off-the-shelf" CAR-T therapy demonstrated significant reductions in molecular residual disease (MRD) and achieved MRD clearance in patients with large B-cell lymphoma. Researchers at the University of Chicago developed GA1CAR, a modular "plug-and-play" CAR-T system offering enhanced safety and adaptability.
University of Chicago Researchers Successfully Engineer CAR T Cells In Vivo for Cancer Treatment
Researchers have reported the first successful in vivo engineering of CAR T cells at a therapeutic level for both hematologic and solid cancers. This advancement, developed by the University of Chicago, aims to make treatments more efficient and precise by engineering T cells within the patient's body. This approach could potentially overcome challenges associated with ex vivo manufacturing.
C406 CAR-T therapy shows significant potential in preclinical cancer studies
C406 CAR-T therapy has demonstrated significant potential in preclinical studies for treating various cancers. This therapy is designed to overcome common challenges in CAR-T treatment, such as tumor resistance and T-cell exhaustion. Further research is ongoing to optimize its efficacy and safety profile for potential clinical translation.
March 2026 — 1 developments
Baylor College of Medicine and Texas Children's Hospital researchers report CAR T-cell therapy safety and benefit in sarcoma trial
A novel CAR T-cell therapy targeting the HER2 antigen has demonstrated safety and clinical benefit in patients with advanced sarcoma during a Phase 1 clinical trial. Researchers at Baylor College of Medicine and Texas Children's Hospital are leading this study. Another related study reported on a second-generation CAR T-cell therapy targeting p95HER2, which showed safety and complete, durable responses in preclinical models.
January 2026 — 1 developments
New CRISPR-based screening methods identify gene targets to enhance CAR T-cell activity
New CRISPR-based screening methods are presented, identifying gene targets that could further enhance CAR T-cell proliferation and anti-tumor activity, indicating ongoing efforts to refine CAR-T technologies.
December 2025 — 1 developments
GCAR1 Clinical Trial for Solid Tumors to Start January 2026
A clinical trial for a different CAR-T therapy (GCAR1), an autologous CAR-T for solid tumors, is first posted, with a study start date of January 31, 2026, indicating ongoing clinical translation efforts in CAR-T for solid tumors.
August 2025 — 1 developments
Review article discusses UCAR-T cell engineering and clinical strategies
A review article discusses the broader landscape of UCAR-T cell engineering and clinical strategies, noting progress in hematological malignancies but persistent challenges in solid tumors, underscoring the importance of GA1CAR's advancements.
May 2025 — 1 developments
International clinical trial shows promising outcomes for new universal CAR-T cell therapy
An international Phase 1/2 clinical trial for a new universal CAR-T cell therapy for aggressive T cell cancers showed promising outcomes, including high response and remission rates with manageable toxicity.
November 2024 — 1 developments
Universal CAR-T Therapy Receives FDA Breakthrough Status for T-Cell Cancers
A universal CAR-T therapy targeting aggressive T-cell cancers has received FDA Breakthrough Status, showing a high overall response rate in a clinical trial. Additionally, a new 'armored' CAR-T cell therapy, enhanced with IL-18, has demonstrated significant responses in lymphoma patients resistant to existing CAR-T treatments.
October 2021 — 1 developments
Universal CAR-T cell therapy gains attention for overcoming manufacturing and cost limitations
The concept of Universal CAR-T (UCAR-T) cell therapy gains significant attention as a strategy to overcome the manufacturing and cost limitations of autologous CAR-T.
August 2017 — 1 developments
U.S. FDA approves Kymriah, first CAR T-cell therapy, for acute lymphoblastic leukemia
The U.S. FDA grants approval to Kymriah (tisagenlecleucel), the first CAR T-cell therapy, for acute lymphoblastic leukemia (ALL), marking a major regulatory and clinical breakthrough.
January 2010 — 1 developments
University of Pennsylvania achieves complete remission in CLL patient with CAR T-cells
The first successful clinical application of CAR T-cells in a patient with chronic lymphocytic leukemia (CLL) at the University of Pennsylvania achieves complete remission, demonstrating the therapy's potential.
January 2003 — 1 developments
Dr. Michel Sadelain's Group Introduces CD19-Targeting CAR T Cells
Dr. Michel Sadelain's group introduces CD19-targeting CAR T cells, a pivotal development that sets the stage for effective CAR T-cell therapies in hematological malignancies.
January 1993 — 1 developments
Landmark studies demonstrate ability to genetically engineer human T cells to kill cancer
Landmark studies demonstrate the ability to genetically engineer human T cells to recognize and kill cancer, and the first-generation CARs are created, though initial in vivo efficacy is limited.
January 1987 — 1 developments
Researchers Propose Foundational Concept of Chimeric Antigen Receptors (CARs)
The foundational concept of chimeric antigen receptors (CARs) is first proposed by researchers, laying the theoretical groundwork for CAR T-cell therapy.